LGMD2I/R9 rAAV Gene Therapy(Bayer)

N/A

Report date: 2024/08/30 17:51:14

Base Information

Drug NameLGMD2I/R9 rAAV Gene Therapy(Bayer)
Drug Alias NameLION-101AB-1003(AskBio)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionRibitol 5-phosphate transferase FKRP gene transference
TargetsRibitol 5-phosphate transferase FKRP
Therapy Area/IndicationsLimb girdle muscular dystrophy 2ANervous System DiseasesMuscular Dystrophies, Limb-Girdle +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAskBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAskBio IncBayer AG
Inactive CompaniesN/A
Active IndicationsLimb girdle muscular dystrophy 2ANervous System DiseasesMuscular Dystrophies, Limb-Girdle +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A